LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”) unveils its Winter 2025-26 issue, featuring the re-release of rarely seen, semi-nude images of Jane Birkin — the global icon and namesake of the world’s most famous handbag — originally published by the magazine in 1970. The pictorial is revisited through the lens of journalist Marisa Meltzer, whose new book It Girl explores Birkin’s enduring influence on women today. The issue officially hits newsstands ...

Flagship system marks Plug’s first commercial electrolyzer deployment in the Netherlands and serves as a path for future Dutch hydrogen hub developmentsSLINGERLANDS, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced it has started installation of its 5 MW electrolyzer for the H2 Hollandia project, the first decentralized green hydrogen hub initiative currently under construction in the Netherl ...

CALGARY, Alberta, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Bocana Resources Corp. (TSXV: BOCA) (Frankfurt: VC1) ("Bocana" or the "Company") is pleased to provide an update to its current activities in Arizona, Colorado, and with our funding/tokenization platform partner Arizore Ltd. In Arizona, the recently drilled samples and portions of the previously cored samples have been shipped to several accredited independent laboratories for varying assay analysis. In the Arizona project in Pinal County, there are Bureau ...

Total committed capital of US $140m for restart of Bogoso and Prestea mine secured from two separate institutional backers (US $75m Equity Line of Credit, still undrawn, and new US $65m1 secured loan) Blue Gold ready to drop litigation with the Government of Ghana if the lease dispute is resolved instantly Restart of Bogoso and Prestea mine ties in with Blue Gold’s strategy to tokenise gold to launch world’s first global gold-backed currency NEW YORK, NY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limit ...

– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks – – On-track to report top-line results from VALIANT Phase 2 trial in severe asthma in the first quarter of 2026 – – Enrollment ongoing in VENTURE Phase 2 trial in COPD; first patient dosed in July – WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. ...

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held at the InterContinental Boston in Boston, MA on Wednesday, November 12, 2025 at 10:00 a.m. Eastern Time. A we ...

Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction study to support initiation of PreciSION CF Phase 2a Initiated Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers Topline data from both trials anticipated in mid-2026 Maintained strong cash position with approximately ...

Third Quarter 2025 Highlights Revenue increased 14% to €292 millionGenerated profit for the period of €22 million, 7.7% as a percentage of revenueAdjusted EBITDA1 increased 29% to €85 million and Adjusted EBITDA margin1 expanded to a record 29.0%Generated net cash from operating activities of €115 million and Free cash flow1 of €65 millionAchieved a Customer Net Retention Rate1 of 114%Raised 2025 full year outlook to revenue of at least €1,290 million, or 17% growth, and Adjusted EBITDA of at least €290 mil ...

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefitReported an interim analysis of the long-term data from the VELA-1 and VELA-2 clinical tri ...